Otsuka Holdings Co., Ltd.
2026 Midterm Financial Results | Record High Profit with 12.8% Revenue Growth
For the fiscal year ending December 2026, revenue reached 1.3323 trillion yen (12.8% increase), with midterm profit hitting 218.5 billion yen (24.3% increase), setting a new record. Segment performance was also strong, driven by the healthcare-related and Nutraceuticals segments.
Key Figures
- Revenue: 1,332,390 million yen (YoY 12.8% increase)
- Midterm Profit: 218,542 million yen (YoY 24.3% increase)
- Net income attributable to owners of the parent: 215,612 million yen (YoY 24.3% increase)
AI要約
Performance Overview
Otsuka Holdings recorded a midterm revenue of 1.3323 trillion yen (up 12.8% YoY) and a midterm profit of 218.5 billion yen (up 24.3% YoY) for the fiscal period ending December 2026, reaching new highs. The strong performance of the healthcare and Nutraceuticals segments substantially contributed to the growth in revenue and profit, particularly driven by increased sales of antipsychotics and anticancer agents. R&D expenses also increased, supporting progress in new drug candidates and expansion through acquisitions. Both assets and liabilities increased, and treasury stock acquisitions and dividend payouts were also implemented.
Outlook and Impact on Shareholders
Full-year earnings forecast for 2026 has been revised upward, with expected revenue of 2.725 trillion yen (an increase of 205 billion yen from previous forecast) and net profit of 360 billion yen (an increase of 91 billion yen). Continued growth in sales of antipsychotics and anticancer drugs, along with ongoing R&D efforts, underpin steady performance. Shareholder returns via treasury stock acquisitions and increased dividends are expected to continue, making the company attractive to investors. While forex and geopolitical risks should be considered, the growth strategy is viewed as sound.
Otsuka Holdings Co., Ltd.
Company overview · Stock price · Financial data · All IR
